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Abstract Tumor-associated macrophages (TAMs) have been implicated in promoting tumor growth and
development. Here we present evidence that demonstrates that co-inoculation of male athymic nude mice with PC-3
prostate cancer cells and U937 promonocytic cells enhances tumor growth and increases tumor angiogenesis. Male
athymic nude mice were co-inoculated with PC-3 and U937 cells (control or IL-4 stimulated) and tumor growth
was monitored over time. Immunohistochemical analysis of tumor specimens was performed for proliferation
markers (e.g., Ki67) and the effects of IL-4 stimulation on U937 cells were analyzed for chemokine expression. The
presence of U937 cells increased the rate of tumor growth in vivo and stimulated increased microvascular density within
the tumor bed. Stimulation of U937 cells with IL-4 resulted in a significant increase in several pro-angiogenic and
pro-tumor chemokines (e.g., CCL2). Co-inoculation increases prostate cancer growth via upregulation of chemokines that
induce angiogenesis within the tumor. J. Cell. Biochem. 103: 1–8, 2008.  2007 Wiley-Liss, Inc.
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The role of tumor-associated macrophages
(TAMs) in prostate cancer metastasis has not
been well investigated. Macrophages can be
‘‘polarized’’ towards one of two phenotypically
different subsets of macrophages: TH1 (also
known as M1 macrophage) or TH2 (also known
as M2 macrophage) [Sica et al., 2006]. M1
macrophages are known to produce pro-inflam-
matory cytokines and play an active role in cell
destruction while M2 macrophages primarily
scavenge debris and promote angiogenesis and
wound repair [Sica et al., 2006]. Recently, the
M2 macrophage population is thought to be
phenotypically similar to the TAM population
that promotes tumor growth and development.
Recently, we have reported the role of CCL2
(monocyte chemoattractant protein 1; MCP-1)
in prostate cancer growth in vitro [Loberg et al.,
2006a]. CCL2, as well as CCL7 and CCL8, is an
important chemokine that is known to regulate
monoctye/macrophage trafficking and has been
reported to be present in several solid tumor
beds [Negus et al., 1997; Kelly et al., 1998; Van
Damme et al., 2004]. The mechanism that
induces the biological change from a tumor
destructive macrophage to a tumor promoting
TAM is not understood. Several hypotheses
have been suggested including alternative cyto-
kine release from the tumor cells that induces a
phenotypic switch in the macrophage popula-
tion. Interleukin 4 (IL-4) has been implicated as
an important cytokine inducing the differentia-
tion of classical macrophages into alternative
macrophages [Hart et al., 1999]. The role of IL-4
in regulating the differentiation of monocytes/
macrophages into TAMs in prostate cancer has
not been reported. Here we present evidence
that demonstrates that co-inoculation of male
athymic nude mice with PC-3 prostate cancer
cells and U937 promonocytic cells enhance
tumor growth and increases tumor angiogen-
esis. Further, stimulation of U937 cells with
IL-4 prior to inoculation enhanced tumor
growth in vivo and stimulated angiogenesis
within the tumor bed.
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Human Recombinant Interlukin-4 (hrIL-4)
was obtained from R&D systems; Drabkin’s
Reagent, containing Potassium Ferricyanide,
Potassium Cyanide, and Sodium Bicarbonate,
was obtained from RICAA Chemical Company.
Cell Culture
U-937 cells are a promonocytic cell line
purchased from ATCC and can be induced to
terminal monocytic differentiation phorbol
esters [Sundstrom and Nilsson, 1976]. U-937
cells and PC-3 prostate cancer cell lines were
maintained in RPMI 1,640þ 10% fetal bovine
serum (FBS). HDMVEC cells were maintained
in complete endothelial cell growth mediumþ
10% FBS. U937 cells were grown in suspension
and were split for passaging while PC-3 cells
and HDMVEC cells were passaged by trypsini-
zation using 1 TrypsinþEDTA (Invitrogen
Corp., Carlsbad, CA), resuspended in appro-
priate growth medium, and used within 10 pas-
sages of each other for consistency. Peripheral
blood mononuclear cells (PBMCs) were isolated
from peripheral blood from a 33-year-old
healthy male. Monocytes were isolated using
CD14þ magnetic bead selection (Miltenyi, Inc.)
IL-4 stimulated U937 cells (U937IL-4) were
incubated in SF RPMIþ IL-4 at a concentration
of 10 ng/ml for 72 h. All cell lines were incubated
at 378C in 5% CO2.
Xenograft Model of Tumorigenesis
Xenograft tumors were established as pre-
viously described [Loberg et al., 2006b]. Briefly,
male athymic mice (5–6 weeks) were injected
subcutaneously with 1 105 PC-3 cells with or
without 1 104 U937 cells or 1 104 U937IL-4
cells in 200 ml Matrigel (BD Biosciences, Inc.). A
second group of male athymic mice (5–6 weeks)
were injected subcutaneously with 1 105 PC-3
cells with or without 1 104 PBMCs or 1 104
PBMCsIL-4 cells in 200 ml Matrigel (BD Bio-
sciences, Inc.). Four mice were assigned to
each group. Tumor volumes were calculated by
caliper measurement performed weekly to
monitor and track tumor growth (tumor
volume¼LWW 0.56). Tumors were har-
vested once the tumor reached the predefined
critical mass of 1,000 mm3.
Histology
Xenograft tumors were harvested and placed
in fresh 10% formalin. Tumors were paraffin
embedded and 5 mm sections were cut and
placed on glass slides. Hematoxylin and eosin
stain was performed per the manufacturer’s
instructions (Sigma, Inc.). Identification of
macrophages was accomplished by labeling
with an anti-CD68 antibody, identification of
neovascularization was accomplished by label-
ing with an anti-CD31 antibody, cell prolifera-
tion was identified using a Ki-67 antibody, and
apoptosis was identified using Apoptag. Tissue
sections were incubated for 10 min in Citrate
buffer, pH6.0 and microwaved. Samples were
then incubated with anti-CD68 (DakoCytoma-
tion, Inc.; 1:1,000), anti-CD31 (DakoCytoma-
tion, Inc.; 1:50), Ki67 (DakoCytomation, Inc.;
1:50), or Apoptag (Chemicon, Inc.) for 30 min
and detected with LSABþdetection/DAB (3,30-
Diaminobenzidine; Sigma, Inc.) for 5 min.
Slides were dipped in hematoxylin for 1 s as a
counterstain.
Microvascular Density
CD31 stained slides were viewed at 100
magnification, representative images were
taken, and microvessels were counted. Indivi-
dual vessels were counted and the data is
presented as the averages for each group and
expressed as number of vessels per 100
objective field.
Hemoglobin Assay
Xenograft tumors were harvested, weighed,
and incubated in 1 ml of Drabkin’s Reagent and
left rocking at 48C for 1 week. Drabkin’s
Reagent converts the total hemoglobin in a
sample to its cyanoderivative, cyanmethemo-
globin which can be used to quantify total
hemoglobin content in a sample. Absorbance
was read at 450 nm, and total hemoglobin
values (mg/ml per 1 g of tissue) were calculated
from a hemoglobin curve prepared from a
standard.
Conditioned Media
Five lakhs cells per well were plated and
allowed to adhere overnight. The following day,
media was aspirated off and 1 ml of fresh serum
free media was added. Conditioned media was
collected either 24 or 72 h later.
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Endothelial Tube Formation Assay
In vitro tube formation was performed as
previously described [Zhou et al., 2004]. Growth
factor reduced Matrigel was diluted with cold
serum-free medium to a concentration of 10 mg/
ml. Fifty microliters of the solution was added to
each well of a 96-well plate and allowed to form a
gel at 378C for 30 min. HDMVEC cells (150,000
cells/ml) in SF RPMI, RPMIþ 10% FBS, U937
CM, or PC-3 CM were added to each well and
incubated overnight at 378C in 5% CO2. Under
these conditions, EC will form delicate networks
of tubes that are detectable within 2–3 h and are
fully developed after 8–12 h. After incubation
the wells were washed, and the Matrigel and its
endothelial tubes were fixed with 3% parafor-
maldehyde.
Proliferation Assay
Cells were seeded at a density of 1 105 cells/
ml for PC-3 cells and 5 105 cells/ml for U937
cells in a 96 well plate in RPMIþ 10% FBS.
Twenty-four hours after seeding, media was
changed to either serum free RPMI, RPMIþ
10% FBS, or conditioned media from either PC-
3 or U937 cells. Cell growth was determined 72 h
later using the WST-1 assay (Pierce Biotech,
Inc.) following the manufacturer’s instructions.
Cytokine/Chemokine Analysis By Bio-Plex Assay
Cytokines and chemokines were measured
using a human 27-plex cytokine panel (Bio-Rad,
Hercules, CA) following the manufacturer’s
instructions. Briefly, cytokine/chemokine stan-
dards were prepared in the same fresh medium
that was used for culturing the cells and were
assayed in duplicate. To each well, beads coated
with antibody to each chemokine or cytokine
were mixed with either standards, samples, or a
blank in a final volume of 100 ml and incubated
for 30 min with continuous shaking (300 rpm) at
room temperature. After washing, biotinylated
antibodies were added for 30 min with con-
tinuous shaking followed by streptavidin–
phycoerythrin (PE) for 10 min. The fluorescence
intensity of the beads was measured using
the Bio-Plex 200 system and Bio-Plex Manager
4.1 software with five-parametric-curve fitting
was used for data analysis.
Real Time RT-PCR
Total RNA was isolated from cell lines using
Trizol (Invitrogen Corp.) following the manu-
facturer’s specifications. Purified RNA (5 mg)
was converted to cDNA using Super Script II
reverse transcriptase (Invitrogen Corp.) follow-
ing the manufacturer’s instructions and used
for gene expression analysis by real time PCR
using an ABI Prism 7900 HT thermocycler.
Primers and probes were purchased from Appli-
ed Biosystems, Inc. and used with TaqMan1
Universal PCR Master Mix, No AmpErase1
UNG. GAPDH was used as an internal control
to normalize and compare each sample. Cycle
conditions for real time PCR were 958C (15 s),
608C (1 min), 728C (1 min) for 40 cycles.
Threshold cycle number for each sample was
normalized to GAPDH for that sample and
expressed on a log scale relative to GAPDH
expression.
Statistical Analyses
Data was analyzed with GraphPad Prizm
software. A One-way-ANOVA analysis was used
with Bonferroni’s post-hoc analysis for compar-
ison between multiple groups. A Students t-test
was used for comparison between two groups.
Significance was defined as a P value <0.05.
RESULTS
The affects of monoctyes on prostate cancer
growth were assessed in vivo using a xenograph
mouse model. PBMCs from a normal, healthy
adult male and the U937 premonocytic cell line
were used. Athymic nude mice were subcuta-
neously injected with PC-3 prostate cancer cells
alone or in combination with monocytes or
monocytes pre-stimulated with IL-4 (10 ng/ml
for 72 h). Average weekly tumor growth for each
group was determined by weekly caliper mea-
surement for co-innoculation with PBMCs
(Fig. 1A) or U937 cells (Fig. 1B). As a control, a
group of mice received xenograft implants of
PBMCs only or U937 cells only (data not
shown). Injection of 1 104 PBMCs or U937
cells into athymic mice failed to develop into
palpable subcutaneous tumors after 10 weeks.
Co-innoculation of athymic nude mice with PC-
3þU937IL-4 cells and PC-3þU937 cells signifi-
cantly decreased the time to critical tumor mass
(1,000 mm3) compared to PC-3 alone (median
time in weeks—PC-3þU937IL-4: 6.5 weeks, PC-
3þU937: 7 weeks, PC-3: 12 weeks; P< 0.05)
(data not shown). The presence of macrophages
in the xenograft tumor bed was confirmed by
CD68þ staining (Fig. 1C–H). Interestingly, the
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PC-3 only xenograft contained CD68þ cells
suggesting host (mouse) macrophage infiltra-
tion into the tumor bed after inoculation
(Fig. 1C).
The presence of TAMs in tumor growth and
progression has previously been associated with
increased tumor angiogenesis [Crowther et al.,
2001]. Thus, the xenograft tumors were har-
vested after each mouse reached the critical
tumor mass, and the affects of co-inoculation
with U937 cells on angiogenesis in the tumor
environment were analyzed using both the
Drabkin’s hemoglobin assay and immunohisto-
logical staining for CD31 and microvascular
density (MVD). MVD analysis revealed a sig-
nificant increase in vascularization in PC-
3þU937 and PC-3þU937IL-4 tumors compared
to PC-3 only tumors and IL-4 pretreated PC-3
tumors (PC-3þU937: 292.0 143.8, PC-3þ
U937IL-4: 380.3 106.6, PC-3IL4: 106 40.9,
and PC-3: 85.5 38.0; meanSD, P< 0.01)
(Fig. 2A). Similarly, analysis of hemoglobin
content using the Drabkin’s assay revealed that
co-innoculation of PC-3 cells with U937 cells
increased tumor hemoglobin concentration.
Specifically, PC-3 tumors had an average con-
centration (mg/ml per 1 g of tissue) of
1.44 1.00, PC-3IL4 2.046 0.76, PC-3þU937
7.92 3.54, and PC-3þU937IL-4 7.37 4.73
(meanSD) (Fig. 2B). To further assess the
role of secreted factors by U937 cells in combi-
nation with PC-3 prostate cancer cells on
enhanced tumor angiogenesis, conditioned
media from U937 or PC-3 cells was used for an
in vitro tube formation assay. HDMVEC cells
were incubated overnight on reduced growth
factor MatrigelTM and allowed to form a branch-
ing network of capillary-like tubes. Incubation
with U937IL-4 CM revealed a significant
increase (P< 0.01) in tube formation as com-
pared to U937 CM, PC-3 CM, and SF media
(Fig. 2C).
To address the hypothesis that macrophages
work in concert with prostate cancer cells to
promote growth and neo-angiogenesis of the
tumor, U937 conditioned media was analyzed
for cytokine/chemokine expression. PC-3 condi-
tioned media is shown as a control for the
cytokines/chemokines that would be present in
the in vivo co-innoculation experiments. Of the
twenty-seven cytokines/chemokines analyzed
U937 cells produce IL-8, IL-9, IL-10, IP-10,
MCP-1 (CCL2), RANTES (CCL5), and VEGF
at >1,000 pg/ml (IL-8: 1,896 348.2, IL-9:
1,340 358.0, IL-10: 1,595 409.5, IP-10:
2,254 689.3, MCP-1 (CCL2): 4,970 1,607,
RANTES(CCL5): 1,560 465.4, and VEGF:
5,061 819.9 pg/ml; meanSD) (Fig. 3A). After
stimulation of U937 cells with IL-4 (10 ng/ml)
for 72 h, conditioned media was analyzed for
cytokine/chemokine expression. IL-1ra, IL-8,
IL-9, IL-10, IP-10, MCP-1 (CCL2), RANTES
(CCL5), and VEGF were expressed at >1,000
pg/ml and significantly elevated compared to
Fig. 1. Co-inoculation of athymic mice with PC-3 and monocytes. A: PC-3 co-inoculated with normal
PBMCs. Tumor volumes were monitored weekly by caliper measurement in PC-3 (-*-), PC-3IL4 (-&-), PC-
3þPBMC (-*-) and PC-3þ PBMC7IL4 (-&-). B: PC-3 co-inoculated with U937 cells. Tumor volumes were
monitored weekly by caliper measurement in PC-3 (-&-), PC-3þU937 (-*-) and PC-3þU937IL4 (-&-).
C–H: Tumor sections from PC-3 co-inoculation with U937 cells were analyzed by IHC for the presence of
macrophages (CD68) and morphology (H&E).
4 Craig et al.
U937 cell conditioned media alone (IL-1ra:
1,253.45 122.92, IL-8: 3,352.07 75.14, IL-9:
2,294.06 170.51, IL-10: 2,547.23 90.86, IP-
10: 3,592.7 82.87, MCP-1 (CCL2): 7,693.27
37.31, RANTES(CCL5): 2,595.69 189.42, and
VEGF: 8,527.14 615.28 pg/ml; meanSD,
P< 0.05) (Fig. 3A). PC-3 cells produce high
levels of IL-6, G-CSF, and VEGF and low levels
of CCL2. Based on these findings, we confirmed
MCP-1 (CCL2) expression in the xeongraft
tumors from PC-3 only tumors as potential
mediators of the increased angiogenesis and
tumor growth and compare them to PC-3þ
U937 and PC-3þU937IL-4 tumors by quantita-
tive real time PCR (Fig. 3B). CCL2 mRNA
expression was found to be significantly ele-
vated in PC-3þU937 and PC-3þU937IL-4 com-
pared to PC3 only or PC-3IL4 tumors (P< 0.01).
Confirmation of the in vivo prostate cancer
cell proliferation was seen both by histology
and by an in vitro proliferation assay. Staining
of xenografts with Ki67, a cell proliferation
marker, revealed increased cell proliferation in
PC-3þU937 and PC-3þU937IL-4 tumors (PC-
3<PC-3þU937<PC-3þU937IL-4) (Fig. 4A–C).
There was no significant difference observed in
the amount of apoptosis as detected by Apoptag
immunohistochemical staining (Fig. 4D–F).
Further, to determine if factors secreted by
U937 cells influenced PC-3 cell growth in vitro,
PC-3 cells were incubated in the presence of
U937 CM for 72 h. PC-3 cells incubated in U937
CM (either unstimulated or IL-4 stimulated)
demonstrated a significant increase in pro-
liferation compared to the serum free media
control (SFM: 0.94 0.16, IL4: 0.89 0.11,
U937 CM: 1.644 0.25, U937IL-4 CM: 1.633
0.32, P< 0.01) (Fig. 4G). Additionally, to
address the question of prostate cancer cell-
dependent regulation of macrophage cell pro-
liferation, U937 cells were incubated in PC-3
CM. PC-3 CM induced a significant increase in
U937 cell proliferation compared to the serum
free control cells (SFM: 0.47 0.01, PC3 CM:
0.75 0.12, P< 0.001) (Fig. 4H).
DISCUSSION
In order to investigate the role of macrophage
infiltration in prostate cancer growth, we
established a xenograft model where PC-3
prostate cancer cells were co-inoculated with
either normal PBMCs or the U937 premonocytic
cell line. U937 cells were originally isolated
from the pleural effusion of a patient with
histiocytic lymphoma but are not terminally
differentiated. The initial experiment (Fig. 1)
compared the response of PC-3 prostate cancer
cells to co-inoculation with normal PBMCs and
U937 cells. PC-3 prostate cancer cells responded
similarly to normal PBMCs and U937 cells.
Fig. 2. The presence of U937 cells induces tumor angiogenesis
in vivo. Tumor vasculature was identified by IHC analysis of
CD31 positive staining (A–C). D: Microvascular density was
counted per 100 objective field from three independent fields
per tumor. Data is displayed as mean SD and significance was
determined with a *P<0.001 and #P<0.05. E: Hemaglobin
content was measured in tumor specimens using the Drabkin’s
reagent and displayed as the amount of hemoglobin (mg/ml) per
gram of tissue for each tumor (mean SD, *P< 0.001 and
#P<0.05). F: Tube formation assay on growth factor reduced
matrigel using HDMVEC cells was preformed with condition-
ed media from PC-3, PC-3IL4, U937, and U937IL4 conditioned
media. The number of endothelial sprouts were counted per
100 objective field from three independent areas and repeated
in triplicate. Data is displayed as themean SD and significance
was determined with a *P< 0.001 and #P<0.01.
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Co-inoculation of PC-3 and PBMCs or U937
cells resulted in a significant increase in tumor
growth in vivo. Prestimulation of monocytes
prior to xenograft implantation resulted in a
further increase in tumor growth compared to
unstimulated monocytes. Logrank analysis of
time to critical tumor mass (tumors >1,000 mm3)
revealed a significant trend (w2¼ 3.842, P<
0.05) in tumors co-inoculated with U937 cells.
These data support the hypothesis that the
presence of tumor infiltrating monocytes/
macrophages promotes prostate cancer growth.
Fig. 3. Stimulation of U937 cells with IL4 induces chemokine expression. A: Analysis of chemokine
expression fromPC-3cells (dashedbars),U937 (openbars), andU937cells stimulatedwith IL-4 (10ng/ml for
72 h) (closed bars) was preformed using a multi-plex assay platform. IL-1ra, IL-8, IL-9, MCP1 (CCL2), and
VEGF were significantly upregulated (P<0.05) after IL-4 stimulation. B: CCL2 mRNA expression in tumor
specimens isolated from PC-3, PC-3þU937, or PC-3-U937IL4 was confirmed by quantitative real time PCR
and normalized to GAPDH levels using the DCT method.
Fig. 4. The presence of U937 cells stimulated PC-3 growth. The effects of U937 cells on PC-3 cell
proliferation were analyzed by IHC for Ki67 staining (A–C) and apoptosis using Apoptag (D–F). G: In vitro
analysis of PC-3 proliferationwas determined byWST-1 assay using IL4 (10 ng/ml), conditionedmedia from
U937 cells or U937IL4 cells. Serum free media (SFM) or serum media (10% FBS) was used as controls
(*P<0.01). H: In vitro analysis of U937 proliferation was determined by WST-1 assay using conditioned
media from PC-3 cells (*P<0.01).
6 Craig et al.
The difference between tumor destructive
macrophages and tumor-promoting macro-
phages is not clearly understood; however,
several reports have suggested that stimulation
of recruited monoctyes with IL-4 induces a
tumor-promoting phenotype and results in
TAM formation [Mantovani et al., 1992]. Prior
to co-inoculation, we pre-stimulated U937 cells
with IL-4 (10 ng/ml) for 72 h. Surprisingly, no
difference in overall tumor growth and time to
critical tumor mass was observed between
untreated U937 cells and IL-4 treated U937
cells. There was a significant increase in
actively proliferating cells as evident by Ki67
immunohistochemical analysis in xenografts
comprised of PC-3þU937 cells compared to
PC-3 cells alone. The presence of TAMs in
various neoplastic tissue has been implicated
in stimulating increased tumor angiogenesis,
and this effect on increased tumor vascularity is
a prominent feature of tumor-promoting macro-
phages. Thus, we assessed the vascular content
of the xenograft tumors. There was a significant
increase in microvascular density (MVD) in
tumors from PC-3þU937 cells compared to PC-
3 cells alone. Further, pre-stimulation of U937
cells with IL-4 did not significantly increase the
amount of neovascularization found within the
xenograft tumors. Interestingly, when condi-
tioned media from PC-3 cells, U937 cells, or
U937 cells pre-stimulated with IL-4 was used
in an in vitro tube formation assay to mimic
neoangiogenesis, a significant increase in the
number of sprouts (tube formation) was identi-
fied in the U937IL-4 conditioned media. These
data suggest that in an in vitro model IL-4
stimulated U937 cells induce angiogenesis;
however, in an in vivo model the role of IL-4
may be lost due to additional factors (including
endogenous IL-4) present in the xenografts.
In order to understand the role of IL-4
stimulated U937 cells and their potential for
influencing prostate cancer growth and induct-
ing angiogenesis within the tumor bed, we
collected 24 h conditioned media from U937
cells and U937IL-4 cells and analyzed cytokine/
chemokine expression using the Luminex tech-
nology. U937 cell conditioned media contained
high levels (>1,000 pg/ml) of several cytokines
(IL-8, IL-9, IL-10, IP-10, MCP1 (CCL2),
RANTES (CCL5), and VEGF). Prior stimula-
tion of U937 cells with IL-4 significantly
increased the levels of IL-1ra, IL-8, IL-9,
MCP1 (CCL2), and VEGF. The role of CCL2 in
regulating the migration and proliferation of
cancer epithelial cells has been suggested in
breast cancer and multiple myeloma [Valkovic
et al., 1998; Ohta et al., 2002; Vanderkerken
et al., 2002; Lebrecht et al., 2004]. Recently we
have reported that CCL2 is elevated in the
prostate cancer tumor microenvironment of
metastatic lesions [Loberg et al., 2006a] and to
influence prostate cancer growth in vitro
[Loberg et al., 2006a; Lu et al., 2006] however
it remains unclear as to the mechanism of
increased CCL2 expression. Currently the role
of monocytes on tumor cell proliferation is
unclear but our data demonstrates that mono-
cytes, and specifically monocytes stimulated
with IL-4, increase the neovascularization of
prostate cancer tumors and that CCL2 plays a
significant role in regulating monocyte infiltra-
tion and vascularization of prostate neoplasias.
In addition, these data suggest that stimulation
of U937 cells with IL-4 induces a TAM pheno-
type and upregulates several cytokines and
chemokines (specifically CCL2) that are impor-
tant in prostate cancer tumor growth and that
stimulate angiogenesis within the tumor bed.
CONCLUSION
Although relatively few studies have char-
acterized the differential expression of chemo-
kines and chemokine receptors found on
prostate cancer cells and in the prostate tumor
microenvironment, it is apparent that chemo-
kines secreted by infiltrating macrophages play
a pivotal role in regulating prostate cancer cell
growth and metastasis. It is unclear what the
predominant chemokine(s) are in the regulation
of prostate cancer growth and metastasis, and if
they are most influential as direct mediators of
tumor cell growth or if their prominent role is
regulating the microenvironment within which
the tumor cells thrive (i.e., angiogenesis, infil-
tration of tumor-promoting immune cells, etc)
[Lissbrant et al., 2000; Lewis and Pollard,
2006]. Lin and Pollard [2004] demonstrated in
breast cancer a positive correlation between
poor prognosis and the degree of TAM infilt-
ration [Lin and Pollard, 2004]. These data
coupled with our preliminary data demons-
trating increased tumor growth with the co-
inoculation of macrophages in prostate cancer
suggest an important role for chemokines and
their receptors in prostate cancer metastasis
and progression. Further investigations into
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the mechanisms of chemotaxis and migration
via chemokine signaling would lead to new
therapeutic strategies for cancer.
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